(Q37266401)

19 August 2017

Risk factors for hepatocellular carcinoma in patients with drug-resistant chronic hepatitis B (English)

1 reference

19 August 2017

hepatocellular carcinoma

1 reference

1 reference

1 reference

Chung Hwan Jun

1

1 reference

19 August 2017

Hyoung Ju Hong

2

1 reference

19 August 2017

Min Woo Chung

3

1 reference

19 August 2017

Seon Young Park

4

1 reference

19 August 2017

Sung Bum Cho

5

1 reference

19 August 2017

Chang Hwan Park

6

1 reference

19 August 2017

Young Eun Joo

7

1 reference

19 August 2017

Hyun Soo Kim

8

1 reference

19 August 2017

Sung Kyu Choi

9

1 reference

19 August 2017

Jong Sun Rew

10

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 October 2013

1 reference

World Journal of Gastroenterology

19 August 2017

1 reference

19 August 2017

19

1 reference

19 August 2017

40

1 reference

19 August 2017

6834-6841

1 reference

Impact of serum C-reactive protein level on the prognosis of patients with hepatocellular carcinoma undergoing TACE.

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3812482

Prognostic role of C-reactive protein in hepatocellular carcinoma: a systematic review and meta-analysis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3812482

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3812482

Antiviral therapy of chronic hepatitis B.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3812482

Introduction to chronic hepatitis B infection

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3812482

Lamivudine for patients with chronic hepatitis B and advanced liver disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3812482

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3812482

Management of chronic hepatitis B.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3812482

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3812482

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3812482

Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3812482

Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3812482

Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3812482

Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3812482

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3812482

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3812482

Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3812482

[Practice guideline for diagnosis and treatment of hepatocellular carcinoma].

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3812482

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3812482

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3812482

Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3812482

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

3 December 2018

1 reference

12 December 2020

EASL clinical practice guidelines

1 reference

12 December 2020

Lamivudine for chronic delta hepatitis

1 reference

12 December 2020

1 reference

12 December 2020

New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy

1 reference

12 December 2020

Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival

1 reference

12 December 2020

A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients

1 reference

12 December 2020

Identifiers

DOI

10.3748/WJG.V19.I40.6834

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

24187458

1 reference